These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
299 related articles for article (PubMed ID: 27311401)
1. Phase I trial of palbociclib, a selective cyclin dependent kinase 4/6 inhibitor, in combination with cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma. Michel L; Ley J; Wildes TM; Schaffer A; Robinson A; Chun SE; Lee W; Lewis J; Trinkaus K; Adkins D Oral Oncol; 2016 Jul; 58():41-8. PubMed ID: 27311401 [TBL] [Abstract][Full Text] [Related]
2. Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial. Adkins D; Ley J; Neupane P; Worden F; Sacco AG; Palka K; Grilley-Olson JE; Maggiore R; Salama NN; Trinkaus K; Van Tine BA; Steuer CE; Saba NF; Oppelt P Lancet Oncol; 2019 Sep; 20(9):1295-1305. PubMed ID: 31351869 [TBL] [Abstract][Full Text] [Related]
3. A Phase I Study of the CDK4/6 Inhibitor Palbociclib in Combination with Cetuximab and Radiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma. Ngamphaiboon N; Pattaranutaporn P; Lukerak S; Siripoon T; Jinawath A; Arsa L; Shantavasinkul PC; Taonam N; Trachu N; Jinawath N; Kositwattanarerk A; Sananmuang T; Jiarpinitnun C Clin Cancer Res; 2024 Jan; 30(2):294-303. PubMed ID: 37982827 [TBL] [Abstract][Full Text] [Related]
4. Palbociclib and cetuximab in cetuximab-resistant human papillomavirus-related oropharynx squamous-cell carcinoma: A multicenter phase 2 trial. Oppelt P; Ley JC; Worden F; Palka K; Maggiore R; Liu J; Adkins D Oral Oncol; 2021 Mar; 114():105164. PubMed ID: 33465681 [TBL] [Abstract][Full Text] [Related]
5. Palbociclib and cetuximab compared with placebo and cetuximab in platinum-resistant, cetuximab-naïve, human papillomavirus-unrelated recurrent or metastatic head and neck squamous cell carcinoma: A double-blind, randomized, phase 2 trial. Adkins DR; Lin JC; Sacco A; Ley J; Oppelt P; Vanchenko V; Komashko N; Yen CJ; Wise-Draper T; Lopez-Picazo Gonzalez J; Radulovic S; Shen Q; Thurm H; Martini JF; Hoffman J; Huang X; Melichar B; Tahara M Oral Oncol; 2021 Apr; 115():105192. PubMed ID: 33571736 [TBL] [Abstract][Full Text] [Related]
6. Palbociclib inhibits the progression of head and neck cancer and improves the Cetuximab response under specific condition in vitro and in vivo. Li R; Wang Q; Zhao Y; Zhu Y; Wang X Mol Biol Rep; 2024 Mar; 51(1):455. PubMed ID: 38536540 [TBL] [Abstract][Full Text] [Related]
7. A phase I study of avelumab, palbociclib, and cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma. Dennis MJ; Sacco AG; Qi Y; Bykowski J; Pittman E; Chen R; Messer K; Cohen EEW; Gold KA Oral Oncol; 2022 Dec; 135():106219. PubMed ID: 36279618 [TBL] [Abstract][Full Text] [Related]
8. Pazopanib plus cetuximab in recurrent or metastatic head and neck squamous cell carcinoma: an open-label, phase 1b and expansion study. Adkins D; Mehan P; Ley J; Siegel MJ; Siegel BA; Dehdashti F; Jiang X; Salama NN; Trinkaus K; Oppelt P Lancet Oncol; 2018 Aug; 19(8):1082-1093. PubMed ID: 30001987 [TBL] [Abstract][Full Text] [Related]
9. A phase 1 study of concurrent cabozantinib and cetuximab in recurrent or metastatic head and neck squamous cell cancer. Desilets A; Pfister DG; Stein S; Wong W; Sherman EJ; Fetten J; Hung TKW; Kriplani A; Dunn LA; Ho AL; Michel LS Oral Oncol; 2024 Jul; 154():106861. PubMed ID: 38795600 [TBL] [Abstract][Full Text] [Related]
10. A pilot study of cetuximab and the hedgehog inhibitor IPI-926 in recurrent/metastatic head and neck squamous cell carcinoma. Bowles DW; Keysar SB; Eagles JR; Wang G; Glogowska MJ; McDermott JD; Le PN; Gao D; Ray CE; Rochon PJ; Roop DR; Tan AC; Serracino HS; Jimeno A Oral Oncol; 2016 Feb; 53():74-9. PubMed ID: 26705064 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of CDK4/CDK6 Enhances Radiosensitivity of HPV Negative Head and Neck Squamous Cell Carcinomas. Göttgens EL; Bussink J; Leszczynska KB; Peters H; Span PN; Hammond EM Int J Radiat Oncol Biol Phys; 2019 Nov; 105(3):548-558. PubMed ID: 31271827 [TBL] [Abstract][Full Text] [Related]
12. CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment. DeMichele A; Clark AS; Tan KS; Heitjan DF; Gramlich K; Gallagher M; Lal P; Feldman M; Zhang P; Colameco C; Lewis D; Langer M; Goodman N; Domchek S; Gogineni K; Rosen M; Fox K; O'Dwyer P Clin Cancer Res; 2015 Mar; 21(5):995-1001. PubMed ID: 25501126 [TBL] [Abstract][Full Text] [Related]
13. A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma. Gilbert J; Schell MJ; Zhao X; Murphy B; Tanvetyanon T; Leon ME; Neil Hayes D; Haigentz M; Saba N; Nieva J; Bishop J; Sidransky D; Ravi R; Bedi A; Chung CH Oral Oncol; 2015 Apr; 51(4):376-82. PubMed ID: 25593015 [TBL] [Abstract][Full Text] [Related]
14. SWOG S1400C (NCT02154490)-A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy). Edelman MJ; Redman MW; Albain KS; McGary EC; Rafique NM; Petro D; Waqar SN; Minichiello K; Miao J; Papadimitrakopoulou VA; Kelly K; Gandara DR; Herbst RS J Thorac Oncol; 2019 Oct; 14(10):1853-1859. PubMed ID: 31302234 [TBL] [Abstract][Full Text] [Related]
15. The Potential for Selective Cyclin-Dependent Kinase 4/6 Inhibition in the Therapy for Head and Neck Squamous Cell Carcinoma. Adkins D; Ley J; Cohen J; Oppelt P Cancer J; 2022 Sep-Oct 01; 28(5):377-380. PubMed ID: 36165726 [TBL] [Abstract][Full Text] [Related]
16. Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib. Bagegni N; Thomas S; Liu N; Luo J; Hoog J; Northfelt DW; Goetz MP; Forero A; Bergqvist M; Karen J; Neumüller M; Suh EM; Guo Z; Vij K; Sanati S; Ellis M; Ma CX Breast Cancer Res; 2017 Nov; 19(1):123. PubMed ID: 29162134 [TBL] [Abstract][Full Text] [Related]
17. Palbociclib-based high-throughput combination drug screening identifies synergistic therapeutic options in HPV-negative head and neck squamous cell carcinoma. Gu Z; Shi C; Li J; Han Y; Sun B; Zhang W; Wu J; Zhou G; Ye W; Li J; Zhang Z; Zhou R BMC Med; 2022 May; 20(1):175. PubMed ID: 35546399 [TBL] [Abstract][Full Text] [Related]
18. Clinical benefit of nanoparticle albumin-bound-paclitaxel in recurrent/metastatic head and neck squamous cell carcinoma resistant to cremophor-based paclitaxel or docetaxel. Ley J; Wildes TM; Daly K; Oppelt P; Adkins D Med Oncol; 2017 Feb; 34(2):28. PubMed ID: 28078561 [TBL] [Abstract][Full Text] [Related]
19. A Kinome-Wide Synthetic Lethal CRISPR/Cas9 Screen Reveals That mTOR Inhibition Prevents Adaptive Resistance to CDK4/CDK6 Blockade in HNSCC. Goto Y; Koshizuka K; Ando T; Izumi H; Wu X; Sato K; Ishikawa T; Ford K; Feng X; Wang Z; Arang N; Allevato MM; Kishore A; Mali P; Gutkind JS Cancer Res Commun; 2024 Jul; 4(7):1850-1862. PubMed ID: 38954773 [TBL] [Abstract][Full Text] [Related]
20. A multi-center phase II trial evaluating the efficacy of palbociclib in combination with carboplatin for the treatment of unresectable recurrent or metastatic head and neck squamous cell carcinoma. Swiecicki PL; Durm G; Bellile E; Bhangale A; Brenner JC; Worden FP Invest New Drugs; 2020 Oct; 38(5):1550-1558. PubMed ID: 31981071 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]